In a major global expansion move, Sun Pharmaceutical Industries has announced the acquisition of U.S.-based Organon & Co in an all-cash transaction valued at approximately $11.75 billion, including debt. This marks the largest overseas buyout ever by an Indian pharmaceutical firm.
The deal aligns with Sun Pharma’s strategy to strengthen its presence in high-margin specialty therapies, particularly in segments like dermatology, oncology, and obesity. The company is also aiming to counter pressure on its U.S. business, where shifting tariff structures have impacted profitability.
Despite the scale of the acquisition, analysts believe it may not significantly alter Sun Pharma’s footprint in the U.S. market, given Organon’s relatively limited presence there. However, the financial upside is substantial. According to Shrikant Akolkar of Nuvama Institutional Equities, the acquisition is expected to double Sun’s revenue and EBITDA, adding around $6.2 billion in annual sales with strong margins of nearly 30%. He also estimates earnings per share could rise by 30% to 40% by FY28.
Investor sentiment reacted positively, with Sun Pharma’s shares closing 7% higher, boosting its market valuation by ₹271.36 billion, after earlier surging as much as 9% during the session.
Sun Pharma, currently valued at over $40 billion, is offering $14 per share for Organon, representing a premium of more than 24% over its April 24 closing price. Organon’s shares jumped 16% in premarket trading following the announcement.
The acquisition will be financed through a mix of internal cash reserves and committed bank loans. As of December 31, 2025, Organon carried net debt of about $8.6 billion, while Sun Pharma maintained a relatively low debt level of $198.4 million and reported profits of $1.16 billion.
Akolkar noted that Sun’s strong balance sheet should help ease debt concerns within three years, positioning the company for stronger global dominance by the end of the decade.
Strategically, the deal enhances Sun Pharma’s portfolio in women’s health and provides an entry into biosimilars. It also brings access to Organon’s wide range of over 70 products, marketed across nearly 140 countries, giving Sun greater global reach and a steady revenue stream alongside its specialty drug pipeline.
This acquisition signals a decisive step in Sun Pharma’s global growth journey, strengthening its specialty portfolio while expanding its international footprint. If executed well, the deal could reshape the company’s long-term positioning as a leading global pharma player.
(Logo courtesy: facebook/SunPharmaLive)